Edition:
India

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

8.81HKD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
HK$8.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,617,298
52-wk High
HK$9.86
52-wk Low
HK$3.95

Select another date:

Tue, May 8 2018

Photo

AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million

LONDON British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million, as part of a strategy to focus on other therapy areas.

AstraZeneca sells rights for Seroquel to Luye Pharma for $538 mln

LONDON, May 8 British pharma company AstraZeneca said it had sold the rights for Seroquel, a treatment for schizophrenia and bipolar disease, to Luye Pharma Group for $538 million, as part of a strategy to focus on other therapy areas.

BRIEF-Luye Pharma Group Acquires Astrazeneca's Rights Relating To Seroquel And Seroquel XR

* ANNOUNCES ACQUISITION OF ASTRAZENECA'S RIGHTS RELATING TO SEROQUEL AND SEROQUEL XR IN CHINA AND IN OTHER TERRITORIES

BRIEF-Luye Pharma Group Says LY03003 Drug Approved To Proceed To Phase III Clinical Trials In China

* LY03003 OBTAINED APPROVAL FROM CHINA FOOD AND DRUG ADMINISTRATION TO PROCEED TO PHASE III CLINICAL TRIALS IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Posts FY Profit Attributable Of RMB981.4 Million​

* ‍FY PROFIT ATTRIBUTABLE ROSE 10.1% TO RMB981.4 MILLION​ Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Announces collaboration With Excel Biopharma

* Immuno-Oncology Antibody Drug Development Collaboration With Excel Biopharm

BRIEF-Luye Pharma Group Says ‍Rotigotine Exempted From Phase 2 Dosage Exploration Clinical Trials​

* ‍ROTIGOTINE EXTENDED RELEASE MICROSPHERES FOR INJECTION IS EXEMPTED FROM PHASE II DOSAGE EXPLORATION CLINICAL TRIALS​ Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Says ‍CFDA Accepted Clinical Trial Application For Co's Anti-Tumor Drug

* ‍CFDA OFFICIALLY ACCEPTED CLINICAL TRIAL APPLICATION FOR ANTI-TUMOR DRUG Source text for Eikon: Further company coverage:

BRIEF-Luye Pharma Group Says FDA To Waive Pediatric Clinical Trials Of Schizophrenia Drug

* FDA AGREES TO WAIVE PEDIATRIC CLINICAL TRIALS OF SCHIZOPHRENIA DRUG LY03004

BRIEF-Luye Pharma Group's Drug Approved By U.S. FDA

* ‍GROUP'S DRUG ROTIGOTINE EXTENDED RELEASE MICROSPHERES FOR INJECTION HAS BEEN APPROVED BY U.S. FDA

Select another date: